Trial Profile

TAXUS V: De Novo Lesion: A Randomized, Double-Blind Trial to Assess TAXUS Paclitaxel-Eluting Coronary Stents, SR Formulation, in the Treatment of De Novo Coronary Lesions

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary)
Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis
Focus Therapeutic Use
Acronyms TAXUS-V
Sponsors Boston Scientific Corporation

Most Recent Events

09 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
21 Sep 2009 Results presented at the 21st Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
25 Sep 2008 FDA approval received for TAXUS stent.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com